Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822267 | 0.93 | DRD4 (0.48) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL25822248 | 0.93 | DRD4 (0.48) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL25822292 | 0.92 | DRD4 (0.47) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL16594348 | 0.86 | MAOB (0.56) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL19291498 | 0.85 | HTR1B (0.60) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL25822204 | 0.83 | GAA (0.54) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL29818753 | 0.83 | TAAR1 (0.56) | MAOBBCHETSHRSPHK2 | |
| SCHEMBL2204438 | 0.83 | TAAR1 (0.56) | MAOBBCHETSHRSPHK2 | |
| SCHEMBL25822235 | 0.82 | DRD4 (0.59) | ADRA1DADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL25821885 | 0.81 | BCHE (0.53) | ADRA1DADRA1AADRA1BDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ADRA1D 409/4885ADRA1A 1026/4885ADRA1B 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.